The Phase 2/3 trial for Inovio’s vaccine was expected to start this month. Photo: /Associated Press By Jared S. Hopkins
A planned later-stage trial for a Covid-19 vaccine from Inovio Pharmaceuticals Inc. INO -27.27% is on hold, after U.S. health regulators raised questions, the company said.
The delay means the Phase 2/3 trial for Inovio’s experimental vaccine won’t begin until October at the earliest.
Inovio shares fell as much as 33% on Monday after the trial hold was announced. The
Read More At Article Source | Article Attribution